These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 20538619)

  • 1. Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy.
    Valori CF; Ning K; Wyles M; Mead RJ; Grierson AJ; Shaw PJ; Azzouz M
    Sci Transl Med; 2010 Jun; 2(35):35ra42. PubMed ID: 20538619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice.
    Dominguez E; Marais T; Chatauret N; Benkhelifa-Ziyyat S; Duque S; Ravassard P; Carcenac R; Astord S; Pereira de Moura A; Voit T; Barkats M
    Hum Mol Genet; 2011 Feb; 20(4):681-93. PubMed ID: 21118896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.
    Foust KD; Wang X; McGovern VL; Braun L; Bevan AK; Haidet AM; Le TT; Morales PR; Rich MM; Burghes AH; Kaspar BK
    Nat Biotechnol; 2010 Mar; 28(3):271-4. PubMed ID: 20190738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the therapeutic window in a severe animal model of spinal muscular atrophy.
    Robbins KL; Glascock JJ; Osman EY; Miller MR; Lorson CL
    Hum Mol Genet; 2014 Sep; 23(17):4559-68. PubMed ID: 24722206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV9-Stathmin1 gene delivery improves disease phenotype in an intermediate mouse model of spinal muscular atrophy.
    Villalón E; Kline RA; Smith CE; Lorson ZC; Osman EY; O'Day S; Murray LM; Lorson CL
    Hum Mol Genet; 2019 Nov; 28(22):3742-3754. PubMed ID: 31363739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN depletion decreases disease severity and modestly prolongs survival in a mouse model of spinal muscular atrophy.
    Little D; Valori CF; Mutsaers CA; Bennett EJ; Wyles M; Sharrack B; Shaw PJ; Gillingwater TH; Azzouz M; Ning K
    Mol Ther; 2015 Feb; 23(2):270-7. PubMed ID: 25369768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
    Passini MA; Bu J; Richards AM; Treleaven CM; Sullivan JA; O'Riordan CR; Scaria A; Kells AP; Samaranch L; San Sebastian W; Federici T; Fiandaca MS; Boulis NM; Bankiewicz KS; Shihabuddin LS; Cheng SH
    Hum Gene Ther; 2014 Jul; 25(7):619-30. PubMed ID: 24617515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.
    Meyer K; Ferraiuolo L; Schmelzer L; Braun L; McGovern V; Likhite S; Michels O; Govoni A; Fitzgerald J; Morales P; Foust KD; Mendell JR; Burghes AH; Kaspar BK
    Mol Ther; 2015 Mar; 23(3):477-87. PubMed ID: 25358252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV9-Mediated Expression of SMN Restricted to Neurons Does Not Rescue the Spinal Muscular Atrophy Phenotype in Mice.
    Besse A; Astord S; Marais T; Roda M; Giroux B; Lejeune FX; Relaix F; Smeriglio P; Barkats M; Biferi MG
    Mol Ther; 2020 Aug; 28(8):1887-1901. PubMed ID: 32470325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A large animal model of spinal muscular atrophy and correction of phenotype.
    Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
    Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy.
    Passini MA; Bu J; Roskelley EM; Richards AM; Sardi SP; O'Riordan CR; Klinger KW; Shihabuddin LS; Cheng SH
    J Clin Invest; 2010 Apr; 120(4):1253-64. PubMed ID: 20234094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice.
    Benkhelifa-Ziyyat S; Besse A; Roda M; Duque S; Astord S; Carcenac R; Marais T; Barkats M
    Mol Ther; 2013 Feb; 21(2):282-90. PubMed ID: 23295949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy.
    Glascock JJ; Shababi M; Wetz MJ; Krogman MM; Lorson CL
    Biochem Biophys Res Commun; 2012 Jan; 417(1):376-81. PubMed ID: 22172949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early heart failure in the SMNDelta7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery.
    Bevan AK; Hutchinson KR; Foust KD; Braun L; McGovern VL; Schmelzer L; Ward JG; Petruska JC; Lucchesi PA; Burghes AH; Kaspar BK
    Hum Mol Genet; 2010 Oct; 19(20):3895-905. PubMed ID: 20639395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.
    Arnold W; McGovern VL; Sanchez B; Li J; Corlett KM; Kolb SJ; Rutkove SB; Burghes AH
    Neurobiol Dis; 2016 Mar; 87():116-23. PubMed ID: 26733414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic treatment with lithium does not improve neuromuscular phenotype in a mouse model of severe spinal muscular atrophy.
    Dachs E; Piedrafita L; Hereu M; Esquerda JE; Calderó J
    Neuroscience; 2013 Oct; 250():417-33. PubMed ID: 23876328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How far away is spinal muscular atrophy gene therapy?
    Gillingwater TH; Murray LM
    Expert Rev Neurother; 2015; 15(9):965-8. PubMed ID: 26189552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic administration of a recombinant AAV1 vector encoding IGF-1 improves disease manifestations in SMA mice.
    Tsai LK; Chen CL; Ting CH; Lin-Chao S; Hwu WL; Dodge JC; Passini MA; Cheng SH
    Mol Ther; 2014 Aug; 22(8):1450-1459. PubMed ID: 24814151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.